logo

For the Inventor, By the Inventor

Dreieich, Germany

Biotest Ag


USPTO Granted Patents = 45

% Expired Patents = 37.8



Trademarks = 10

Forward Citations = 271

Loading Chart...
Loading Chart...

65 inventors (with patents filed for the assignee):

goldMedal Benjamin Daelken (17 out of 18 patents)

silverMedal Frank Osterroth (14 out of 14 patents)

bronzeMedal Christoph Bruecher (14 out of 14 patents)

4.  Christoph Uherek (14 out of 14 patents)

5.  Matthias Germer (11 out of 12 patents)

6.  Andrea Wartenberg-Demand (10 out of 10 patents)

7.  Gregor Schulz (8 out of 8 patents)

8.  Silke Aigner (8 out of 8 patents)

9.  Oliver Maneg (7 out of 8 patents)

10.  Dieter Rudnick (7 out of 14 patents)

11.  Chantal Zuber (7 out of 7 patents)

12.  André Engling (7 out of 7 patents)

13.  Wolfgang Moeller (6 out of 7 patents)

14.  Michael Rodemer (6 out of 6 patents)

15.  John Wijdenes (6 out of 11 patents)


Core Competencies:
Immunoglobulin Compositions
Antibody Preparations
Immunoconjugates
Systemic Lupus Erythematosus
Severe Pneumonia
CD138 Targeting
Humanized Antibodies
Viral Infections
Antibody Detection
Polypeptides
Cytotoxic Side-Effects
Therapeutic Agents

45 patents:

1. 12487244 - Method and kit for testing potency of immunoglobulin compositions (2025-12-02),
2. 12264191 - De-immunized factor VIII molecule and pharmaceutical compositions comprising the same (2025-04-01),
3. 12186391 - Treatment of severe community acquired pneumonia (2025-01-07),
4. 11780909 - Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM (2023-10-10),
5. 11517621 - Treatment of severe community acquired pneumonia (2022-12-06),
6. 11325964 - Process for preparing immunoglobulin compositions (2022-05-10),
7. 10954290 - IgG, IgA and IgM antibody preparations, method of making and method of use in treatment (2021-03-23),
8. 10918715 - Treatment of severe community acquired pneumonia (2021-02-16),
9. 10117932 - Uses of immunoconjugates targeting CD138 (2018-11-06),
10. 10059759 - Antibody preparations (2018-08-28),
11. 9995733 - Agents for treating disease (2018-06-12),
12. 9758581 - Humanized anti-CD4 antibody with immunosuppressive properties (2017-09-12),
13. 9605066 - Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) (2017-03-28),
14. 9550831 - Method for treating psoriasis (2017-01-24),
15. 9540436 - Use of antibodies for detection of IL-10 (2017-01-10),
Company Overview
Biotest AG, headquartered in Dreieich, Germany, specializes in the development and manufacturing of immunoglobulin compositions and antibody preparations. The company focuses on innovative therapies targeting systemic lupus erythematosus, severe pneumonia, and viral infections, utilizing advanced technologies such as immunoconjugates and humanized antibodies. Biotest is committed to enhancing patient care through its research in immunology and therapeutic solutions, positioning itself as a key player in the biopharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

45 Patents

#1 in Dreieich

#1,166 in Germany

#15,450 in the World

Dreieich, DE
Dreieich, Germany

Biotest Ag

Forward Citations = 271

65 inventors:

goldMedal Benjamin Daelken (17 out of 18 patents)

silverMedal Frank Osterroth (14 out of 14 patents)

bronzeMedal Christoph Bruecher (14 out of 14 patents)

4.  Christoph Uherek (14 out of 14 patents)

5.  Matthias Germer (11 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biotest Ag. Retrieved from https://idiyas.com/company/biotest-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…